Remy Nyga1, Julien Maizel2,3, Saad Nseir4,5, Taieb Chouaki6, Ivona Milic1, Pierre-Alexandre Roger1, Nicolas Van Grunderbeeck7, Malcolm Lemyze8, Anne Totet1, Sandrine Castelain1, Michel Slama9, Hervé Dupont10,11, Boualem Sendid12,13, Elie Zogheib10. 1. CHU Amiens-Picardie, 36673, Amiens, France. 2. University Hospital of Amiens, Intensive Care Unit, Amiens, France. 3. MP3CV-EA 7517, Amiens, France; maizel.julien@chu-amiens.fr. 4. CHU de Lille, Centre de Réanimation, Lille, France. 5. Université de Lille, Faculté de Médecine, Lille, France. 6. CHU Amiens - Picardie, Medical Parasitology and Mycology Department, Amiens, France. 7. Schaffner Hospital, Infectious Diseases, Lens, France. 8. Schaffner hospital, Respiratory and Critical Care Medicine, Lens, France. 9. CHU Amiens, Réanimation médicale, Amiens, France. 10. CHU Amiens, Anesthesiology and critical care, Amiens, France. 11. Centre universitaire de recherche en santé, INSERM 1088, Amiens, France. 12. CHU Lille, Medical Parasitology and Mycology Department, Lille, France. 13. Université de Lille, INSERM U995, Team Fungal Associated Invasive & Inflammatory Diseases, Lille Inflammation Research International Center, Lille, France.
Abstract
RATIONALE: Invasive tracheobronchial aspergillosis (ITBA) is an uncommon, but severe clinical form of Invasive Pulmonary Aspergillosis (IPA) in which the fungal infection is entirely or predominantly confined to the tracheobronchial tree. OBJECTIVES: To analyze diagnostic and prognostic differences between tracheobronchial aspergillosis and pulmonary aspergillosis without tracheobronchial lesions among patients admitted to the intensive care unit (ICU) with severe influenza. METHODS: This retrospective, observational study included critically ill patients with influenza associated with pulmonary aspergillosis from 3 hospital ICUs between 2010 and 2019. Patient characteristics, clinical and mycological data at admission and during ICU stay were collected in a database to evaluate variables in the two groups. MEASUREMENTS AND MAIN RESULTS: Thirty-five patients admitted to the ICU with severe influenza and pulmonary aspergillosis were included. Ten patients were included in the ITBA group (n=10/35; 28.6%) and 25 patients in the No ITBA group. The ITBA group comprised more patients with active smoking, diabetes mellitus and higher severity scores (SAPSII). Ninety-day mortality in the ITBA and No ITBA groups was 90% and 44% respectively (p=0.02). Moreover, significantly higher serum beta-D glucan and galactomannan, and broncho-alveolar lavage fluid (BALF) galactomannan levels were observed in the ITBA group compared to the No ITBA group (p<0.0001, p=0.003 and p=0.008, respectively). CONCLUSIONS: Invasive tracheobronchial aspergillosis was associated with higher severity scores, mortality, serum and BALF Galactomannan and Beta-D Glucan levels than IPA patients without tracheobronchial lesions. ITBA should be systematically researched by bronchoscopic examination in ICU patients with concomitant pulmonary aspergillosis and influenza.
RATIONALE: Invasive tracheobronchial aspergillosis (ITBA) is an uncommon, but severe clinical form of Invasive Pulmonary Aspergillosis (IPA) in which the fungal infection is entirely or predominantly confined to the tracheobronchial tree. OBJECTIVES: To analyze diagnostic and prognostic differences between tracheobronchial aspergillosis and pulmonary aspergillosis without tracheobronchial lesions among patients admitted to the intensive care unit (ICU) with severe influenza. METHODS: This retrospective, observational study included critically illpatients with influenza associated with pulmonary aspergillosis from 3 hospital ICUs between 2010 and 2019. Patient characteristics, clinical and mycological data at admission and during ICU stay were collected in a database to evaluate variables in the two groups. MEASUREMENTS AND MAIN RESULTS: Thirty-five patients admitted to the ICU with severe influenza and pulmonary aspergillosis were included. Ten patients were included in the ITBA group (n=10/35; 28.6%) and 25 patients in the No ITBA group. The ITBA group comprised more patients with active smoking, diabetes mellitus and higher severity scores (SAPSII). Ninety-day mortality in the ITBA and No ITBA groups was 90% and 44% respectively (p=0.02). Moreover, significantly higher serum beta-D glucan and galactomannan, and broncho-alveolar lavage fluid (BALF) galactomannan levels were observed in the ITBA group compared to the No ITBA group (p<0.0001, p=0.003 and p=0.008, respectively). CONCLUSIONS:Invasive tracheobronchial aspergillosis was associated with higher severity scores, mortality, serum and BALF Galactomannan and Beta-D Glucan levels than IPA patients without tracheobronchial lesions. ITBA should be systematically researched by bronchoscopic examination in ICU patients with concomitant pulmonary aspergillosis and influenza.
Entities:
Keywords:
Aspergillosis; Influenza; Intensive care unit; galactomannan; β-1,3-D-Glucan
Authors: Robinder G Khemani; Jessica T Lee; David Wu; Edward J Schenck; Margaret M Hayes; Patricia A Kritek; Gökhan M Mutlu; Hayley B Gershengorn; Rémi Coudroy Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 21.405
Authors: Frank L van de Veerdonk; Roger J M Brüggemann; Shoko Vos; Gert De Hertogh; Joost Wauters; Monique H E Reijers; Mihai G Netea; Jeroen A Schouten; Paul E Verweij Journal: Lancet Respir Med Date: 2021-05-26 Impact factor: 30.700
Authors: Max Melchers; Arthur R H van Zanten; Moniek Heusinkveld; Jan Willem Leeuwis; Roel Schellaars; Hendrick J W Lammers; Freek J Kreemer; Pieter-Jan Haas; Paul E Verweij; Sjoerd H W van Bree Journal: Crit Care Explor Date: 2022-05-09
Authors: Lore Vanderbeke; Nico A F Janssen; Roger J M Brüggemann; Joost Wauters; Dennis C J J Bergmans; Marc Bourgeois; Jochem B Buil; Yves Debaveye; Pieter Depuydt; Simon Feys; Greet Hermans; Oscar Hoiting; Ben van der Hoven; Cato Jacobs; Katrien Lagrou; Virginie Lemiale; Piet Lormans; Johan Maertens; Philippe Meersseman; Bruno Mégarbane; Saad Nseir; Jos A H van Oers; Marijke Reynders; Bart J A Rijnders; Jeroen A Schouten; Isabel Spriet; Karin Thevissen; Arnaud W Thille; Ruth Van Daele; Frank L van de Veerdonk; Paul E Verweij; Alexander Wilmer Journal: Intensive Care Med Date: 2021-05-29 Impact factor: 17.440
Authors: Paul E Verweij; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Jochem B Buil; Thierry Calandra; Tom Chiller; Cornelius J Clancy; Oliver A Cornely; Pieter Depuydt; Philipp Koehler; Katrien Lagrou; Dylan de Lange; Cornelia Lass-Flörl; Russell E Lewis; Olivier Lortholary; Peter-Wei Lun Liu; Johan Maertens; M Hong Nguyen; Thomas F Patterson; Bart J A Rijnders; Alejandro Rodriguez; Thomas R Rogers; Jeroen A Schouten; Joost Wauters; Frank L van de Veerdonk; Ignacio Martin-Loeches Journal: Intensive Care Med Date: 2021-06-23 Impact factor: 17.440